Abstracts by keywords: international standards
In Germany, health economic instruments for drug evaluation were introduced for the first time through the GKV Modernization Act. The basis for this economic evaluation of medicines is the international standards of health economics, which are explicitly required by law. The draft methods presented by IQWiG have so far been inadequate and have been subject to widespread criticism. The efficiency frontier concept proposed by IQWiG is subject to many methodological shortcomings. In addition, the QALY is strictly rejected as a cross-indication benefit measure. The chosen perspective of the insured community and the close integration of the benefit parameters also do not correspond to the international standard. The IQWiG proposal is therefore not suitable for creating the necessary instructions for carrying out cost-benefit assessments of new medical technologies. A look at the international methods that have been established in many other countries for some time shows all the necessary solutions. This solution will also have an impact on the healthcare research landscape.